Insulet Corporation $PODD Shares Sold by Bank of Nova Scotia

Bank of Nova Scotia lessened its holdings in Insulet Corporation (NASDAQ:PODD) by 86.8% during the 1st quarter, Holdings Channel reports. The firm owned 9,800 shares of the medical instruments supplier’s stock after selling 64,603 shares during the quarter. Bank of Nova Scotia’s holdings in Insulet were worth $2,056,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PODD. Glenmede Investment Management LP lifted its position in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares in the last quarter. Curi Capital LLC increased its position in Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares in the last quarter. Great Lakes Advisors LLC increased its position in Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 40 shares in the last quarter. Camarda Financial Advisors LLC raised its stake in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC raised its stake in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have commented on PODD shares. Truist Financial lowered their target price on shares of Insulet from $219.00 to $210.00 and set a “buy” rating for the company in a research note on Monday, July 13th. TD Cowen reduced their price target on Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a research note on Monday, June 1st. Barclays reduced their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Citigroup raised their price objective on Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Finally, UBS Group downgraded Insulet from a “buy” rating to a “neutral” rating and set a $174.00 price objective for the company. in a research report on Tuesday. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.38.

Insulet Trading Up 1.9%

NASDAQ PODD opened at $170.62 on Thursday. Insulet Corporation has a 52 week low of $138.79 and a 52 week high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a market cap of $11.82 billion, a P/E ratio of 39.68, a PEG ratio of 1.17 and a beta of 1.11. The company’s fifty day simple moving average is $154.87 and its 200-day simple moving average is $199.34.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts predict that Insulet Corporation will post 6.45 EPS for the current fiscal year.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: UBS initiated coverage of Insulet with a “neutral” rating and a $174 price target, implying modest upside from the referenced price. The rating suggests UBS sees a balanced risk-reward profile rather than a strong near-term catalyst. Benzinga reference
• Neutral Sentiment: Multiple law firms reminded investors of an August 31, 2026 deadline to seek lead-plaintiff status in a securities-fraud lawsuit against Insulet and certain executives. The notices reference slightly different class periods, generally covering purchases from February or May 2025 through May 26, 2026. Rosen Law Firm article
• Negative Sentiment: The complaints reportedly allege that defective cannula manufacturing caused insulin under-delivery in millions of Omnipod devices and that Insulet failed to disclose manufacturing deficiencies and product-safety risks. One notice also alleges that executive Eric Benjamin sold approximately $3.7 million of Insulet stock before two medical-device corrections. These are allegations, not established findings, but the litigation could increase costs and intensify scrutiny of Insulet’s quality controls and disclosures. SueWallSt shareholder alert

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.